PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) - Jaeger, U.